OIPE JC113 APR 0 2 2004 PATENT & TRADEMARK OFFICE

OIPE JC113 APR 0 2 2004 PATENT & TRADEMARK OFFICE

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/679,303
Filing Date	10/07/2003
First Named Inventor	Gregory S. Hamilton
Group Art Unit	~~1625~~ 1624
Examiner Name	~~(not yet assigned)~~ K. Habte
Attorney Docket Number	023597-0110

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KH	A1	5,344,944		FRANCKOWIAK ET AL.	09/06/1994	
	A2	4,898,865		FRANCKOWIAK ET AL.	02/06/1990	
	A3	4,876,255		FRANCKOWIAK ET AL.	10/24/1989	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
KH	A4	EP	0 287 867	A1	BAYER AG	10/26/1988		ABS.
	A5	EP	0 287 866	A1	BAYER AG	10/26/1988		ABS.
	A6	EP	0 185 964	A2	BAYER AG	07/02/1986		ABS.
	A7	EP	0 503 079	A1	KAKEN PHARMACEUTICAL CO.	09/16/1992		
	A8	DE	101 10 747	A1	BAYER AG	09/12/2002		ABS.
	A9	EP	0 268 273	A2	WARNER-LAMBERT COMPANY	05/25/1988		
	A10	EP	0 189 254	A1	PFIZER LIMITED	07/30/1986		
	A11	EP	0 119 050	A2	PFIZER LIMITED	09/19/1984		
	A12	EP	0 116 769	A1	PFIZER LIMITED	08/29/1984		
	A13	EP	0 132 375	A2	PFIZER LIMITED	01/30/1985		
	A14	EP	1 302 463	A1	YAMANOUCHI PHARMACEUTICAL CO. LTD.	04/16/2003		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A15	FOREST ET AL., "A Novel Class of Cardiotonic Agents: Synthesis and Biological Evaluation of 5-Substituted 3,6-Dihydrothiadiazin-2-ones with Cyclic AMP Phosphodiesterase Inhibiting and Myofibrillar Calcium Sensitizing Properties", *Journal of Medicinal Chemistry,* American Chemical Society, Vol. 35, No. 1, 1992, pp. 163-172, XP002146828, ISSN: 0022-2623.	
KH	A16	RUMP ET AL., "Effects of Different Inotropes with Antioxidant Properties on acute Regional Myocardial Ischemia in Isolated Rabbit Hearts", *General Pharamacology,* Pergamon Press, Oxford, GB, Vol. 26, No. 3, 1995, pp. 603-611, XP000926014, ISSN: 0306-3623.	
KH	A17	BARALDI ET AL., "Synthesis and Calcium Antagonist Activity of Dialkyl 1,4-Dihydro-2,6-Dimethyl-4-(Nitrogenous Heteroaryl)-3,5-Pyridine Dicarboxylates", *Collect. Czech. Chem. Commun.,* Vol. 57, 1992, pp. 169-178, XP009023953.	

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/679,303
				Filing Date	10/07/2003
				First Named Inventor	Gregory S. Hamilton
				Group Art Unit	~~1625~~ 1624
(use as many sheets as necessary)				Examiner Name	~~(not yet assigned)~~ K. Habte
Sheet	2	of	2	Attorney Docket Number	023597-0110

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A18	ALKER ET AL., "Long Action Dihydropyridine Calcium Antagonists", *Journal of Medicinal Chemistry*, Vol. 33, 1990, pp. 585-591, XP002267026.	

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,303
				Filing Date	10/07/2003
				First Named Inventor	Gregory S. Hamilton
				Group Art Unit	~~1625~~ 1624
(use as many sheets as necessary)				Examiner Name	~~(not yet assigned)~~ K. Kable
Sheet	1	of	1	Attorney Docket Number	023597-0110

OIPE JUN 17 2005 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KK	B1	5,096,904		WHEELER ET AL.	03/17/1992	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,303
				Filing Date	10/07/2003
Date Submitted: January 30, 2004				First Named Inventor	Gregory S. Hamilton
				Group Art Unit	~~1625~~ 624
(use as many sheets as necessary)				Examiner Name	(not yet assigned)
Sheet	1	of	6	Attorney Docket Number	023597-0110

OIPE JC#14 3b
JAN 3 0 2004
PATENT & TRADEMARK OFFICE
K. Kabk

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KH	A1	4,450,165		Araki et al.	05/22/1984	
	A2	4,568,677		Alker et al.	02/04/1986	
	A3	4,564,619		Tanaka et al.	01/14/1986	
	A4	4,590,195		Alker et al.	05/20/1986	
	A5	4,723,014		Anderson et al.	02/02/1988	
	A6	4,820,842		Anderson et al.	04/11/1989	
	A7	5,100,892		Wheeler et al.	03/31/1992	
	A8	5,258,519		Wheeler et al.	11/02/1993	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A9	FOSSHEIM, "Crystal Structure of the Dihydropyridine Ca^{2+} Antagonist Felodipine. Dihydropyridine Binding Prerequisites Assessed from Crystallographic Data," *J. Med. Chem.*, Vol. 29, pp. 305-307, (1986), American Chemical Society	
	A10	TAMAZAWA et al., "Stereoselectivity of a Potent Calcium Antagonist, 1-Benzyl-3-pyrrolidinyl Methyl 2,6-Dimethyl-4-(*m*-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate," *J. Med. Chem.*, Vol. 29, pp 2504-2511, (1986) American Chemical Society	
	A11	SUNKEL et al., "Synthesis of 3-[2,3-Dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl]alkyl] 1,4-Dihydropyridine-3,5-dicarboxylate Derivatives as Calcium Channel Modulators," *J. Med. Chem.*, Vol. 35, pp. 2407-2414, (1992), American Chemical Society	
	A12	ARROWSMITH et al., "Long-Acting Dihydropyridine Calcium Antagonists. 1. 2-Alkoxymethyl Derivatives Incorporating Basic Substituents," *J. Med. Chem.*, Vol. 29, pp. 1696-1702, (1986), American Chemical Society, UK	
	A13	ALKER, et al., "Long-Acting Dihydropyridine Calcium Antagonists. 5. Synthesis and Structure-Activity Relationships for a Series of 2-[[(*N*-Substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine Calcium Antagonists," *J. Med. Chem.*, Vol. 33, pp. 1805-1811, (1990), American Chemical Society, UK	
	A14	ROVNYAK, et al., "Active Conformation of 1,4-Dihydropyridine Calcium Entry Blockers. Effect of Size of 2-Aryl Substituent on Rotameric Equilibria and Receptor Binding," *J. Med. Chem.*, Vol. 34, pp. 2521-2524, (1991), American Chemical Society	
	A15	GOLDMANN, et al., "Synthesis, Pharmacological Effects, and Conformation of 4,4-Disubstituted 1,4-Dihydropyridines," *J. Med. Chem.*, Vol. 33, pp. 1413-1418, (1990), American Chemical Society	

#1133006

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,303
				Filing Date	10/07/2003
Date Submitted: January 30, 2004				First Named Inventor	Gregory S. Hamilton
				Group Art Unit	~~1625~~ 1624
(use as many sheets as necessary)				Examiner Name	~~(not yet assigned)~~ K. Hahr
Sheet	2	of	6	Attorney Docket Number	023597-0110

OIPE JC14 JAN 30 2004 PATENT & TRADEMARK OFFICE

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A16	ATWAL, et al., "Dihydropyrimidine Calcium Channel Blockers: 2-Heterosubstituted 4-Aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," *J. Med. Chem.*, Vol. 33, pp. 1510-1515, (1990), American Chemical Society	
	A17	ATWAL, et al., "Dihydropyrimidine Calcium Channel Blockers. 2.[1] 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," *J. Med. Chem.*, Vol. 33, pp. 2629-2635, (1990), American Chemical Society	
	A18	ALKER, et al., "Long-Acting Dihydropyridine Calcium Antagonists. 4. Synthesis and Structure-Activity Relationships for a Series of Basic and Nonbasic Derivatives of 2-[(2-Aminoethoxy)methyl]-1,4-dihydropyridine Calcium Antagonists," *J. Med. Chem.*, Vol. 33, pp. 585-591, (1990), American Chemical Society	
	A19	NATALE, et al., "Lipophilic 4-Isoxazolyl-1,4-dihydropyridines: Synthesis and Structure-Activity Relationships," *J. Med. Chem.*, Vol. 42, pp. 3087-3093, (1999), American Chemical Society	
	A20	MALHOTRA et al., "Barnidipine," Drugs, Vol. 61, pp. 989-996, (2001), Auckland, New Zealand	
	A21	JOSLYN, et al., "Dimeric 1,4-Dihydropyridines as Calcium Channel Antagonists," *J. Med. Chem.*, Vol. 31, pp. 1489-1492, (1988), American Chemical Society	
	A22	ALKER, et al., "Long-Acting Dihydropyridine Calcium Antagonists. 3. Synthesis and Structure-Activity Relationships for a Series of 2-[(Heterocyclylmethoxy)methyl] Derivatives," *J. Med. Chem.*, Vol. 32, pp. 2381-2388, (1989), American Chemical Society	
	A23	NOVINSON, et al., "3-Substituted 5,7-Dimethylpyrazolo[1,5-α]pyrimidines, 3',5'-Cyclic-AMP Phosphodiesterase Inhibitors," *J. Med. Chem.*, Vol. 17, No. 6, pp. 645, 648, (1974)	
	A24	WEISHAAR, et al., "A New Generation of Phosphodiesterase Inhibitors: Multiple Molecular Forms of Phosphodiesterase and the Potential for Drug Selectivity," *J. Med. Chem.*, Vol. 28, Number 5, pp. 537-545, (1985), American Chemical Society, USA	

#1133006

Examiner Signature		Date Considered	8/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,303
				Filing Date	10/07/2003
Date Submitted: January 30, 2004				First Named Inventor	Gregory S. Hamilton
				Group Art Unit	~~1625~~ 1624
(use as many sheets as necessary)				Examiner Name	~~(not yet assigned)~~ K. Habte
Sheet	3	of	6	Attorney Docket Number	023597-0110

OIPE JC17 JAN 30 2004 PATENT & TRADEMARK OFFICE

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A25	COATES, et al., "Cyclic Nucleotide Phosphodiesterase Inhibition by Imidazopyridines: Analogues of Sulmazole and Isomazole as Inhibitors of the cGMP Specific Phosphodiesterase," *J. Med. Chem.*, Vol. 36, pp. 1387-1392, (1993), American Chemical Society	
	A26	MARIVET, et al., "Inhibition of Cyclic Adenosine-3',5'-monophosphatae Phosphodiesterase from Vascular Smooth Muscle by Rolipram Analogues," *J. Med. Chem.*, Vol. 32, pp. 1450-1457, (1989) American Chemical Society	
	A27	MOOS, et al., "Cardiotonic Agents. 8. Selective Inhibitors of Adenosine 3',5'-Cyclic Phosphate Phosphodiesterase III. Elaboration of a Five-Point Model for Positive Inotropic Activity," *J. Med. Chem.*, Vol. 30, pp. 1963-1972, (1987), American Chemical Society	
	A28	VENUTI, et al., "Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazo[2,1-*b*]quinazoline," *J. Med. Chem.*, Vol. 31, pp. 2136-2145, (1988), American Chemical Society	
	A29	VENUTI, et al., "Inhibitors of Cyclic AMP Phosphodiesterase. 4. Synthesis and Evaluation of Potential Prodrugs of Lixazinone," *J. Med. Chem.*, Vol. 31, pp. 2145-2152, (1988), American Chemical Society	
	A30	SIRCAR, et al., "Cardiotonic Agents, 7. Inhibition of Separated Forms of Cyclic Nucleotide Phosphodiesterase from Guinea Pig Cardiac Muscle by 4,5-Dihydro-6-[4-(1-*H*-imidazol-1-yl)phenyl]-3(2*H*)-pyridazinones and Related Compounds. Structure-Activity Relationships and Correlation with in Vivo Positive Inotropic Activity," *J. Med. Chem.*, Vol. 30, pp. 1955-1962, (1987), American Chemical Society	
	A31	SIRCAR, et al., "Cardiotonic Agents. 9. Synthesis and Biological Evaluation of a Series of (*E*)-4,5-Dihydro-6-[2-[4-(1*H*-imidazol-1-yl)phenyl]ethenyl]-3(2*H*)-pyridazinones: A Novel Class of Compounds with Positive Inotropic, Antithrombotic, and Vasodilatory Activities for the Treatment of Congestive Heart Failure," *J. Med. Chem.*, Vol. 32, pp. 342-350, (1989), American Chemical Society	
	A32	GARST, et al., "Inhibition of Separated Forms of Phosphodiesterases from Pig Coronary Arteries by Uracils and by 7-Substituted Derivatives of 1-Methyl-3-isobutylxanthine," *J. Med. Chem.*, Vol. 19, No. 4, pp. 499-503, (1976),	
	A33	GOODSELL, et al., "8-Substituted Theophyllines. *In Vitro* Inhibition of 3'-5'-Cyclic Adenosine Monoposphate Phosphodiesterase and Pharmacological Spectrum in Mice," *Journal of Medicinal Chemistry*," Vol. 14, No. 12 pp. 1202-1205, (1971)	

#1133006

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,303
				Filing Date	10/07/2003
Date Submitted: January 30, 2004				First Named Inventor	Gregory S. Hamilton
				Group Art Unit	~~1626~~ 1624
(use as many sheets as necessary)				Examiner Name	~~(not yet assigned)~~ K. Habte
Sheet	4	of	6	Attorney Docket Number	023597-0110

OIPE JC17 JAN 30 2004 PATENT & TRADEMARK OFFICE

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A34	MEANWELL, et al., "Inhibitors of Blood Platelet cAMP Phosphodiesterase. 2. Structure-Activity Relationships Associated with 1,3-Dihydro-2*H*-imidazo[4,5-*b*]quinolin-2-ones Substituted with Functionalized Side Chains," *J. Med. Chem.*, Vol. 35, pp. 2672-2687, (1992), American Chemical Society	
	A35	WELLS, et al., "Inhibition of Separated Forms of Cyclic Nucleotide Phosphodiesterase from Pig Coronary Arteries by 1,3-Disubstituted and 1,3,8-Trisubstituted Xanthines," *J. Med. Chem.*, Vol. 24, pp. 954-958, (1981), American Chemical Society	
	A36	SCHNELLER, et al., "Inhibition of Cyclic Nucleotide Phosphodiesterases fro Pig Coronary Artery by Benzo-Separated Analogues of 3-Isobutyl-1-methylxanthine," *J. Med. Chem.*, Vol. 29, pp. 972-978, (1986), American Chemical Society	
	A37	BUCHMAN, et al., "Imidazole Derivatives as Inhibitors of Cyclic Nucleotide Phosphodiesterases," *J. Med. Chem.*, Vol. 17, No. 11 pp. 1168-1173, (1974)	
	A38	LAMPE, et al., "(Imidazolylphenyl)pyrrol-2-one Inhibitors of Cardiac cAMP Phosphodiesterase," *J. Med. Chem.*, Vol. 36, pp. 1041-1047, (1993), American Chemical Society	
	A39	SIRCAR, et al., "Cardiotonic Agents. 3. Synthesis and Biological Activity of Novel 6-(Substituted 1*H*-imidazol-4(5)-yl)-3(2*H*)-pyridazinones," *J. Med. Chem.*, Vol. 29, pp. 261-267, (1986), American Chemical Society	
	A40	NOVINSON, et al., "2-(Alkylthio)-1,2,4-triazolo[1,5-*a*]pyrimidines as Adenosine Cyclic 3',5'-Monophosphate Phosphodiesterase Inhibitors with Potential as New Cardiovascular Agents," *J. Med. Chem.*, Vol. 25, pp. 420-426, (1982) American Chemical Society	
	A41	SIRCAR, et al., "Cardiotonic Agents. 4. Synthesis and Biological Evaluation of N-Substituted 2,4,4a,5-Tetrahydro-3*H*-indeno[1,2-*c*]pyridazin-3-ones: Rigid Structures Derived from CI-930 and Analogues," *J. Med. Chem.*, Vol. 29, pp. 2142-2148, (1986), American Chemical Society	
	A42	SIRCAR, et al., "Cardiotonic Agents. 2. Synthesis and Structure-Activity Relationships of 4,5-Dihydro-6-[4-(1*H*-imidazol-1-yl)phenyl]-3(2*H*)-pyridazinones: A New Class of Positive Inotropic Agents," *J. Med. Chem.*, Vol. 28, pp. 1405-1413, (1985), American Chemical Society	

#1133006

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,303
				Filing Date	10/07/2003
Date Submitted: January 30, 2004				First Named Inventor	Gregory S. Hamilton
				Group Art Unit	~~1625~~ 1624
(use as many sheets as necessary)				Examiner Name	~~(not yet assigned)~~ K. Habte
Sheet	5	of	6	Attorney Docket Number	023597-0110

OIPE JC17 JAN 30 2004 PATENT & TRADEMARK

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A43	HARRISON, et al., "Novel Alkaline Ring Cleavage of 2-Phenyl-3-hydroxythieno[2,3-*b*]quinoline 1,1-Dioxide, a Potent inhibitor of Cyclic Adenosine 5'-Monophosphate Phosphodiesterase," *J. Org. Chem.*, Vol. 44, No. 17, pp. 2977-2979, (1979), American Chemical Society	
	A44	MEANWELL, et al., "Inhibitors of Blood Platelet cAMP Phosphodiesterase. 3. 1,3-Dihydro-2*H*-imidazo[4,5-*b*]quinolin-2-one Derivatives with Enhanced Aqueous Solubility," *J. Med. Chem.*, Vol. 35, pp. 2688-2696, (1992), American Chemical Society	
	A45	SIRCAR, et al., "Calcium Channel Blocking and Positive Inotropic Activities of Ethyl 5-Cyano-1,4-dihydro-6-methyl-2[(phenylsulfonyl)methyl]-4-aryl-3-pyridine-carboxylate and Analogues. Synthesis and Structure-Activity Relationships," *J. Med. Chem.*, Vol. 34, pp. 2248-2260, (1991), American Chemical Society	
	A46	COATES, et al., "1,4-Bis(3-oxo-2,3-dihydropyridazin-6-yl)benzene Analogues: Potent Phosphodiesterase Inhibitors and Inodilators," *J. Med. Chem.*, Vol. 33, pp. 1735-1741, (1990), American Chemical Society	
	A47	SIRCAR, et al., "1,2-Dihydro-5-[4-(1*H*-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3-pyridinecarbonitriles and Related Compounds. Synthesis and Inotropic Activity," *J. Med. Chem.*, Vol. 30, pp. 1023-1029, (1987),	
	A48	NOVINSON, et al., "Adenosine Cyclic 3',5'-Monophosphate Phosphodiesterase Inhibitors. 2. 3-Substituted 5,7-Dialkylpyrazolo[1,5-*a*]pyrimidines," *Journal of Medicine Chemistry*, Vol. 18, No. 5, pp. 460-464	
	A49	SAWANISHI, et al., "Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines," *J. Med. Chem.*, Vol. 40, pp. 3248-3253, (1997), American Chemical Society	
	A50	ARROWSMITH, et al., "Long Acting Dihydropyridine Calcium Antagonists. 2. 2-[2-Aminoheterocycloethoxy]methoxy]methyl Derivatives," *J. Med. Chem.*, Vol. 32, pp. 562-568, (1989), American Chemical Society	
	A51	NISHI, et al., "Studies on 2-Oxoquinoline Derivatives as Blood Platelet Aggregation Inhibitors. III. *N*-Cyclohexyl-*N*(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)-butyramide and Related Compounds," *Chem. Pharm. Bull.*, Vol. 31, No. 3 pp. 852-860, (1983)	

#1133006

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/679,303
Date Submitted: January 30, 2004				**Filing Date**	10/07/2003
				First Named Inventor	Gregory S. Hamilton
(use as many sheets as necessary)				Group Art Unit	~~1625~~ 1624
				Examiner Name	(~~not yet assigned~~) K. Habte
Sheet	6	of	6	Attorney Docket Number	023597-0110

OIPE JC17 JAN 30 2004 PATENT & TRADEMARK OFFICE

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
KH	A52	LUGNIER, et al., "Substituted carbostyrils as inhibitors of cyclic AMP phosphodiesterase," *Eur. J. Med. Chem. – Chim. Ther.*, Vol. 20, No. 2 pp. 121-125, (1985)	
KH	A53	JONES, et al., "Inhibitors of Cyclic AMP Phosphodiesterase. 1. Analogues of Cilostamide and Anagrelide," *J. Med. Chem.*, Vol. 30, pp. 295-303, (1987), American Chemical Society	
KH	A54	Results of computer search in *Chemical Abstracts Registry*, comprising Parts I to IV	

#1133006

Examiner Signature		Date Considered	2/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.